Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
MK0359 · 3 trials · 3 indications
| Name | Type | Description |
|---|---|---|
| MK0359 | DRUG | - |
Inclusion Criteria: * You are between the ages of 40 and 75 * You have had a history for at least a year of COPD symptoms * You have a history of smoking one pack of cigarettes per day for 10 years Exclusion Criteria: * You have been in a research study with an investigational drug or vaccine in ...
MK0359 is an investigational small molecule being studied for chronic obstructive pulmonary disease (COPD), rheumatoid arthritis, and asthma. It is in Phase 2 clinical development and is not approved by the FDA.
MK0359 is being developed by Merck & Company, Inc., which trades under the ticker symbol MRK. The drug is currently in Phase 2 clinical trials.
MK0359 is in Phase 2 clinical development. It is an investigational drug and has not been approved by the FDA. Clinical trials for the drug are completed.
MK0359 has completed Phase 2 trials including NCT00482235 in COPD, NCT00482417 in rheumatoid arthritis, and NCT00482898 in asthma. These trials were randomized and double-blind.
MK0359 is not known by any alternative names. It is a distinct investigational small molecule developed by Merck & Company, Inc. for respiratory and inflammatory conditions.